

PUBLICATIONS 2010

Ph.D. theses

1. Bartels AL. Pathogenic mechanisms in Parkinson's disease: Studies with positron emission tomography. Ph.D.thesis, University of Groningen, February 17, 2010. [Promotores: Leenders KL, **Dierckx RA**. Copromotor: Copray JCVM]. 157 pages.
2. **Doorduyn J**. Herpes viruses and neuroinflammation: PET imaging and implication in schizophrenia. Ph.D.thesis, University of Groningen, January 6, 2010. [Promotor: **Dierckx RA**, Copromotores: **Klein HC, de Vries EFJ**]. 272 pages.
3. Fiebrich HB. Tumor imaging and treatment monitoring in patients with neuroendocrine tumors. Ph.D.thesis, University of Groningen, June 23, 2010. [Promotores: De Vries EGE, Links TP, Kema IP, Copromotor: **Brouwers AH**] 194 pages
4. Krabbe C. Positron emission tomography in staging and surveillance of oral and oropharyngeal squamous cell carcinoma. [Promotores: Roodenburg JLN, Dijkstra PU]. Ph.D.thesis, University of Groningen, October 6, 2010. 141 pages.

Full papers in peer-reviewed international journals

- (1) **Abdoli, M.**, Ay, M. R., Ahmadian, A., **Dierckx, R. A. J. O.**, and **Zaidi, H.** Reduction of dental filling metallic artifacts in CT-based attenuation correction of PET data using weighted virtual sinograms optimized by a genetic algorithm. *Med. Phys.* 2010,37(12):6166-6177.
- (2) **Abdoli, M.**, Ay, M. R., Ahmadian, A., and **Zaidi, H.** A virtual sinogram method to reduce dental metallic implant artefacts in computed tomography-based attenuation correction for PET. *Nucl. Med. Commun.* 2010,31(1):22-31.
- (3) **Agool A, Dierckx RA, de Wolf JT, Vellenga E, Slart RH.** Extramedullary haematopoiesis imaging with (18)F-FLT PET. *Eur J Nucl Med Mol Imaging.* 2010,37(8):1620.
- (4) **Agool A, Slart RH, Dierckx RA, Kluin PM, Visser L, Jager PL, Vellenga,E.** Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma. *Eur J Nucl Med Mol Imaging.* 2010,37(1):124-130.

- (5) **Antunes IF**, Haisma HJ, **Elsinga PH**, **Dierckx RA**, **de Vries EF**. Synthesis and evaluation of [18F]-FEAnGA as a PET Tracer for beta-glucuronidase activity. *Bioconjug Chem.* 2010,21(5):911-920.
- (6) Bartels AL, **de Klerk OL**, Kortekaas R, de Vries JJ, Leenders KL. ¹¹C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease. *Curr Top Med Chem.* 2010; 10(17):1775-84.
- (7) Bartels AL, **Willemsen AT**, **Doorduyn J**, **de Vries EF**, **Dierckx RA**, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? *Parkinsonism Relat Disord.* 2010,16(1):57-59.
- (8) Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, **Pruim J**, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, **Paans AM**, **Willemsen AT**, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. *Eur J Nucl Med Mol Imaging.* 2010,37(1):181-200.
- (9) Breeuwsma AJ, **Pruim J**, van den Bergh AC, Leliveld AM, Nijman RJ, **Dierckx RA**, de Jong, I.J. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. *Int J Radiat Oncol Biol Phys.* 2010,77(1):160-164.
- (10) Bruggink JL, **Glaudemans AW**, Saleem BR, Meerwaldt R, Alkefaji H, Prins TR, **Slart RHJA**, Zeebregts CJ. Accuracy of FDG-PET-CT in the diagnostic work-up of vascular prosthetic graft infection. *Eur J Vasc Endovasc Surg* 2010; 40: 348-354.
- (11) Bruggink JL, Meerwaldt R, van Dam GM, Lefrandt JD, **Slart RH**, Tio RA, Smit AJ., Zeebregts CJ. Spectroscopy to improve identification of vulnerable plaques in cardiovascular disease. *Int J Cardiovasc Imaging.* 2010,26(1):111-119.
- (12) Campbell-Verduyn LS, Szymanski W, Postema CP, **Dierckx RA**, **Elsinga PH**, Janssen DB, Feringa BL. One pot 'click' reactions: tandem enantioselective biocatalytic epoxide ring opening and [3+2] azide alkyne cycloaddition. *Chem Commun (Camb)* . 2010,46(6):898-900.
- (13) Coenen HH, **Elsinga PH**, Iwata R, Kilbourn MR, Pillai MR, Rajan MG, Wagner HN, Zaknun JJ. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences. *Nucl Med Biol.* 2010,37(7):727-740.
- (14) Colabufo NA, **van Waarde A**. Imaging of ABC transporter function and expression. *Curr Top Med Chem.* 2010,10(17):1701-1702.

- (15) Colabufo NA, **van Waarde A**. Molecule of the Month: [¹¹C]MC18, a radiotracer for PET imaging of P-gp expression. *Curr Top Med Chem*. 2010,10(3):383-384.
- (16) D'Alessandria C, **di Gialleonardo V**, Chianelli M, Mather SJ, **de Vries EFJ**, Scopinaro F, **Dierck RA**, **Signore A**. Synthesis and optimization of the labeling procedure of ^{99m}Tc-Hynic-interleukin-2 for in vivo imaging of activated T lymphocytes. *Mol. Imaging Biol.*, 2010,12: 539-546.
- (17) de Bruyn M, **Rybczynska AA**, Wei Y, Schwenkert M, Fey GH, **Dierckx RA**, **van Waarde A**, Helfrich W, Bremer E.. Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. *Mol Cancer*. 2010,9(1):301.
- (18) de Jong IJ, De Haan TD, Wiegman EM, van den Bergh AC, **Pruim J**, Breeuwsma AJ. PET/CT and radiotherapy in prostate cancer. *Q J Nucl Med Mol Imaging*. 2010,54(5):543-552.
- (19) de Jong JS, Beukema JC, van Dam GM, **Slart RH**, **Lemstra C**, Wiggers T. Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up. *Ann Surg Oncol* 2010;17:2656-2662.
- (20) de Jong JS, van Ginkel RJ, **Slart RH**, **Lemstra, C.L.**, **Paans, A.M.**, Mulder, N.H., Hoekstra, H.J. FDG-PET probe-guided surgery for recurrent retroperitoneal testicular tumor recurrences. *Eur J Surg Oncol*. 2010,36(11):1092-1095.
- (21) de Klerk OL, **Willemsen AT**, Bosker FJ, Bartels AL, Hendrikse NH, den Boer JA, **Dierckx RA**. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. *Psychiatry Res*. 2010,183(2):151-156.
- (22) de Klerk OL, Bosker FJ, **Willemsen AT**, **van Waarde A**, **Visser AK**, de Jager T, Dagey G, **den Boer JA**, **Dierckx RA**, Meerlo P. Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats. *J Psychopharmacol*. 2010,24(8):1237-1242.
- (23) **de Vries EF**, Roca M, Jamar F, Israel O, **Signore A**. Guidelines for the labelling of leucocytes with (^{99m}Tc)-HMPAO. *Eur J Nucl Med Mol Imaging*. 2010,37(4):842-848.
- (24) Dijkers EC, Oude Munnink TH, Kosterink JG, **Brouwers AH**, **Jager PL**, **de Jong JR**, van Dongen GA, Schroder CP, **Lub-de Hooge MN**, de Vries EG. Biodistribution of ⁸⁹Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. *Clin Pharmacol Ther*. 2010,87(5):586-592.

- (25) **Doorduyn J, Klein HC, de Jong JR, Dierckx RA, de Vries EF.** Evaluation of [11C]-DAA1106 for imaging and quantification of neuroinflammation in a rat model of herpes encephalitis. *Nucl Med Biol.* 2010,37(1):9-15.
- (26) Dullaart RP, van der Horst-Schrivers AN, **Koopmans KP.** New imaging approaches to pheochromocytomas and paragangliomas. *Clin Endocrinol (Oxf).* 2010,72(4):568-569.
- (27) **Glaudemans AW, Dierckx RA,** Kallenberg CG, Anzola Fuentes KL. The role of radiolabelled anti-TNFalpha monoclonal antibodies for diagnostic purposes and therapy evaluation. *Q J Nucl Med Mol Imaging* 2010; 54: 639-653.
- (28) **Glaudemans AW, Signore A.** FDG-PET/CT in infections: the imaging method of choice? *Eur J Nuc Med Mol Imaging* 2010. 37(10):1986-1991
- (29) **Glaudemans AW, Slart RH,** Bozzao A, Bonanno E, Arca M, **Dierckx RA, Signore A.** Molecular imaging in atherosclerosis. *Eur J Nucl Med Mol Imaging.* 2010,37(12):2381-2397.
- (30) **Glaudemans AW,** Maccioni F, Mansi L, **Dierckx RA, Signore A.** Imaging of cell trafficking in Crohn's disease. *J Cell Physiol.* 2010,223(3):562-571.
- (31) **Golestani R, Wu C,** Tio RA, Petrov AD, Beekman FJ, **Dierckx RA, Boersma HH, Slart RH.** Small-animal SPECT and SPECT/CT: application in cardiovascular research. *Eur J Nucl Med Mol Imaging.* 2010,37(9):1766-1777.
- (32) **Golestani R,** Tio RA, Zeebregts CJ, Zeilstra A, **Dierckx RA, Boersma HH, Hillege HL, Slart RH.** Abdominal aortic calcification detected by dual X-ray absorptiometry: A strong predictor for cardiovascular events. *Ann Med.* 2010,42(7):539-545.
- (33) Haver VG, **Slart RH,** Zeebregts CJ, Peppelenbosch MP, Tio RA. Rupture of vulnerable atherosclerotic plaques: microRNAs conducting the orchestra? *Trends Cardiovasc Med* 2010;20:65-71.
- (34) **Jager PL, Slart RH,** Webber CL, Adachi JD, Papaioannou AL, Gulenchyn KY. Combined Vertebral Fracture Assessment and Bone Mineral Density Measurement: A Patient-Friendly New Tool with an Important Impact on the Canadian Risk Fracture Classification. *Can Assoc Radiol J.* 2010,61(4):194-200.
- (35) Krabbe CA, **Pruim J,** Dijkstra PU, Roodenburg JL. Reply: 18F-FDG PET for Routine Posttreatment Surveillance in Oral and Oropharyngeal Squamous Cell Carcinoma. *J Nucl Med.* 2010,51:1164-1165.

- (36) Krabbe CA, **Pruim J**, Scholtens AM, Roodenburg JL, **Brouwers AH**, **Phan TT**, **Agool A**, Dijkstra PU. 18F-FDG PET in squamous cell carcinoma of the oral cavity and oropharynx: a study on inter- and intraobserver agreement. *J Oral Maxillofac Surg*. 2010,68(1):21-27.
- (37) Krabbe CA, Werff-Regelink G, **Pruim J**, van der Wal JE, Roodenburg JL. Detection of cervical metastases with (11)C-tyrosine pet in patients with squamous cell carcinoma of the oral cavity or oropharynx: A comparison with (18)F-FDG PET. *Head Neck*. 2010,32(3):368-374.
- (38) Kuchenbecker WK, Groen H, Zijlstra TM, Bolster JH, **Slart RH**, van der Jagt EJ, Kobold AC, Wolffenbuttel BH, Land JA, Hoek A. The subcutaneous abdominal fat and not the intraabdominal fat compartment is associated with anovulation in women with obesity and infertility. *J Clin Endocrinol Metab*. 2010,95(5):2107-2112.
- (39) **Luurtsema G**, Boellaard R, Greuter HN, Rijbroek A, Takkenkamp K, de Geest FG, Buijs FL, Hendrikse HN, Franssen EJ, van Lingen A, Lammertsma AA. Pharmaceutical preparation of oxygen-15 labelled molecular oxygen and carbon monoxide gasses in a hospital setting. *J Clin Pharm Ther*. 2010,35(1):63-69.
- (40) **Luurtsema G**, Verbeek GL, Lubberink M, Lammertsma AA, **Dierckx RA**, **Elsinga PH**, Windhorst AD, **van Waarde A**. Carbon-11 Labeled Tracers for In vivo Imaging P-Glycoprotein Function: Kinetics, Advantages and Disadvantages. *Curr Top Med Chem*. 2010,10(17):1820-1833.
- (41) Malviya G, Conti F, Chianelli M, Scopinaro F, **Dierckx RA**, **Signore A**. Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. *Eur J Nucl Med Mol Imaging*. 2010,37(2):386-398.
- (42) Meerwaldt R, **Slart RH**, van Dam GM, Luijckx GJ, Tio RA, Zeebregts CJ. PET/SPECT imaging: from carotid vulnerability to brain viability. *Eur J Radiol*. 2010,74(1):104-109.
- (43) Muijs CT, Beukema JC, **Pruim J**, Mul VE, Groen H, Plukker JT, Langendijk JA. A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. *Radiother Oncol*. 2010,97(2):165-171.
- (44) Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, **de Jong JR**, Jensen MR, Quadt C, Garcia-Echeverria C, van Dongen GA, **Lub-de Hooge MN**, Schroder CP, de Vries EG. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. *J Nucl Med*. 2010,51(5):761-767.

- (45) Nagengast WB, Oude Munnink TH, Dijkers EC, Hospers GA, **Brouwers AH**, Schroder CP, **Lub-de Hooge M**, de Vries EG. Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets. In: J.Zhou (ed.), Multi-Drug Resistance in Cancer. *Methods Mol Biol.* 2010,596:15-31.
- (46) Oude Munnink TH, Dijkers EC, Netters SJ, **Lub-de Hooge MN**, **Brouwers AH**, Haasjes JG, Schroder CP, de Vries EG. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. *J Clin Oncol.* 2010,28(21):e355-e356.
- (47) Oude Munnink TH, Korte MA, Nagengast WB, Timmer-Bosscha H, Schröder CP, **de Jong JR**, van Dongen GA, Jensen MR, Quadt C, **de Hooge MN**, de Vries EG. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. *Eur J Cancer* 2010, 46(3):678-684
- (48) Roca M, **de Vries EF**, Jamar F, Israel O, **Signore A**. Guidelines for the labelling of leucocytes with (111)In-oxine. *Eur J Nucl Med Mol Imaging.* 2010,37(4):835-841.
- (49) Schreurs LM, Busz DM, Paardekooper GM, Beukema JC, **Jager PL**, van der Jagt EJ, van Dam GM, Groen H, Plukker JT, Langendijk JA. Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves esophageal target definition. *Dis Esophagus.* 2010,23(6):493-501.
- (50) Seigers R, Timmermans J, van der Horn HJ, **de Vries EF**, **Dierckx RA**, Visser L, Schagen SB, van Dam FS, Koolhaas JM, Buwalda B. Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. *Behav Brain Res.* 2010,207(2):265-272.
- (51) **Signore A**, Mather SJ, Piaggio G, Malviya G, **Dierckx RA**. Molecular imaging of inflammation/infection: nuclear medicine and optical imaging agents and methods. *Chem Rev.* 2010,110(5):3112-3145.
- (52) **Slart RH**, Tio RA, van der Vleuten PA, Willems TP, Lubbers DD, **Dierckx RA**, van Veldhuisen DJ. Myocardial perfusion reserve and contractile pattern after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy. *J Nucl Cardiol.* 2010,17(3):479-485.
- (53) **Slart RH**. Coronary endothelial function: a clinical role for PET? *Eur J Nucl Med Mol Imaging* 2010;37:2231-2232.
- (54) **Slart RH**, **Glaudemans AW**, **Weijs LE**, Tio RA. Anti-ischemic medication during myocardial perfusion: with or without? *Nucl Med Commun.* 2010,31(2):94-96.

- (55) Smit MD, Tio RA, **Slart RH**, Zijlstra F, Van Gelder IC. Myocardial perfusion imaging does not adequately assess the risk of coronary artery disease in patients with atrial fibrillation. *Europace*. 2010,12(5):643-648.
- (56) Stenekes MW, Coert JH, Nicolai J, Mulder T, Geertzen HB, **Paans AM**, de Jong BM. Cerebral consequences of dynamic immobilisation after primary digital flexor tendon repair. *J Plast Reconstr Aesthet Surg*. 2010,63(12):1953-1961.
- (57) Teune LK, Bartels AL, de Jong BM, **Willemsen AT**, **Eshuis SA**, de Vries JJ, van Oostrom JC, Leenders KL. Typical cerebral metabolic patterns in neurodegenerative brain diseases. *Mov Disord*. 2010,25(14):2395-2404.
- (58) van der Harst P, **Slart RH**, Tio RA, Dunselman PH, **Willemsen AT**, van den Heuvel AF, Voors AA, van Veldhuisen DJ. Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study). *Am J Cardiol*. 2010,105(4):517-521.
- (59) van Gameren II, Hazenberg BP, Bijzet J, Haagsma EB, Vellenga E, Posthumus MD, **Jager PL**, van Rijswijk MH. Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. *Arthritis Care Res* 2010;62:296-301.
- (60) **van Waarde A**, **Rybczynska AA**, **Ramakrishnan N**, Ishiwata K, **Elsinga PH**, **Dierckx RA**. Sigma Receptors in Oncology: Therapeutic and Diagnostic Applications of Sigma Ligands. *Curr Pharm Des*. 2010,16(31):3519-3537.
- (61) Verjans J, Wolters S, Laufer W, Schellings M, Lax M, Lovhaug D, **Boersma H**, Kemerink G, Schalla S, Gordon P, Teule J, Narula J, Hofstra L. Early molecular imaging of interstitial changes in patients after myocardial infarction: Comparison with delayed contrast-enhanced magnetic resonance imaging. *J Nucl Cardiol* 2010, 17: 1065-1070.
- (62) Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, **Slart RH**, Tio RA, van 't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ. A single dose of erythropoietin in ST-elevation myocardial infarction. *Eur Heart J* 2010;31:2593-2600.
- (63) Wiering B, Adang EM, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, **Pruim J**, Dekker HM, Ruers TJ, Krabbe PF, Oyen WJ. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. *Nucl Med Commun*. 2010,31(11):938-944.
- (64) **Wu C**, van der Have F, Vastenhouw B, **Dierckx RA**, **Paans AM**, Beekman FJ. Absolute quantitative total-body small-animal SPECT with focusing pinholes. *Eur J Nucl Med Mol Imaging*. 2010,37(11):2127-2135.

Publications in Dutch journals

- (1) **Glaudemans A, Slart R, Dierckx RA.** Service in the spotlight : Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen. Tijdschr Nucl Geneesk 2010;32(4):630-???
- (2) **Slart R, Glaudemans A, Veltman NC,** van Eck-Smit, BLF. Implementatie E-learningplatform voor nucleair geneeskundigen (i.o.). Tijdschr Nucl Geneesk 32(3):556-557
- (3) Verbeek HHG, de Groot JWB, Plukker JTM, Hofstra RMW, **Brouwers AH,** Kerstens MN, Links TP. Medullair schildklier carcinoom, een tumor met vele gezichten. Ned Tijdschr Geneesk 2010;154:A1818.

Abstracts in international journals

1. **Abdoli, M.,** Ay, M. R., Ahmadian, A., **Dierckx, R. A.,** and Zaidi, H. Optimization of weighted virtual sinogram-based metal artifact reduction in CT-based attenuation correction of PET data using a generic algorithm. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S285. 2010.
2. **Boersma, H. H.,** Elsinga, P. H., Medema, J., Luurtsema, G., **Lub-de Hooge, M. N., Paans, A. M. J.,** Slegers, G., **Dierckx, R. A.,** Kosterink, J. G. W., and **Sturkenboom.M.G.** How to reach compliance for manufacturing of PET-radiopharmaceuticals under current EU-GMP regulations: an approach for university hospitals. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S363. 2010.
3. **De Jong, J. R.,** Schoenahl, F., **Wierds, R., Lazarenko, S., Segbers, M., Dierckx, R. A., Paans, A. M. J.,** and **Willemsen, A. T. M.** NEMA 2007 performance characteristics of the Siemens mCT PET/CT camera. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S333. 2010.
4. **De Jong, J. R., Medema, J., Van Zanten, A. K., Boersma, H. H., Brouwers, A. H., Elsinga, P. H., Glaudemans, A. W., Pruijm, J.,** and **Dierckx, R. A.** Hierarchic risk management in nuclear medicine. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S344. 2010.
5. **De Jong, J. R.,** Oude Munnink, T., **Brouwers, A. H., Dierckx, R. A.,** Perik, P. J., De Vries, E. G., and **Lub-de Hooge, M. N.** Radiation dosimetry of ¹¹¹In-trastuzumab used for HER2-SPECT. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S477. 2010.
6. **De Jong, J. R.,** Warnders, F., **Nagengast, W. B., Dierckx, R. A.,** Hospers, G. A., **Brouwers, A. H.,** De Vries, E. G., and **Lub-de Hooge, M. N.** Radiation dosimetry of ¹¹¹In-bevacizumab used for VEGF-SPECT in melanoma patients. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S477. 2010.

7. **De Klerk OL, Willemsen AT, Bosker FJ, Van Waarde A, Meerlo P, Dierckx RA, Den Boer JA.** The impact of depressive disorders and treatment with an antidepressant on the activity of P-glycoprotein at the blood-brain barrier. *J Affective Disorders* 2010; 122:S39-40.
8. **De Klerk OL.** The impact of P-glycoprotein on antidepressant function. *J Psychopharmacol* 2010; Suppl 3: S18.
9. **De Vries, E. F. J., Uitvlugt, E., Van Waarde, A., Sijbesma, J. W. A., Dierckx, R. A., Wolterbeek, A., and De Groot, D. G. M.** Prenatal and early childhood alcohol exposure causes abnormal brain development. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S210. 2010.
10. **De Vries, E.G.E., Oude Munnink TH, Nagengast WB, Brouwers AH, Schröder CP, van Dongen GAMS, Lub-de Hooge MN.** Use of zirconium-labeled antibodies for tumor imaging: Possible applications for targeted tumor therapy. Keystone conference, January 2010.
11. **Di Gialleonardo, V., De Vries, E. F. J., Chianelli, M., De Vos, P., Dierckx, R. A., and Signore, A.** Detection of insulinitis in diabetic animal models using 18F-FB-IL2 PET. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S265-S266. 2010.
12. **Dobos, N., Prins, M., De Vries, E. F. J., Sijbesma, J. W. A., Doorduyn, J., Van Waarde, A., Kema, I. P., Dierckx, R. A., Luiten, P. G. M., Den Boer, J. A., Nijholt, I., and Eisel, U. L. M.** Indoleamine-2,3-dioxygenase: a link between neuroinflammation and depression in Alzheimer's disease. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S259. 2010.
13. **Doorduyn, J., De Vries, E. F. J., Willemsen, A. T. M., Dierckx, R. A., and Klein, H. C.** Imaging of herpes virus activity in the central nervous system of schizophrenic patients. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S208-S209. 2010.
14. **Doorduyn, J., Klein, H. C., Dierckx, R. A., and De Vries, E. F. J.** HSV-1 induced neuroinflammation and antipsychotic treatment affect P-glycoprotein activity in the rat brain. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S250. 2010.
15. **Doorduyn, J., Klein, H. C., Dierckx, R. A., and De Vries, E. F. J.** The behavioural and dopaminergic response to HSV-1 infection of the brain are affected by ketamine. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S277. 2010.

16. **Doorduyn, J., Klein, H. C., Dierckx, R. A., and De Vries, E. F. J.** [18F]-FDG for imaging of brain metabolism in animal models of human disease: a comparison between intraperitoneal and intravenous injection. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S355. 2010.
17. **Doorduyn, J., Klein, H. C., Dierckx, R. A., and De Vries, E. F. J.** HSV-1 induced behavioural changes and microglia cell activation are inhibited by antipsychotics. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S387-S388. 2010.
18. **Farinha Antunes, I., Haisma, H. J., Elsinga, P. H., Dierckx, R. A., and De Vries, E. F. J.** [18F]-FEAmGA: an improved PET tracer for extracellular β -glucuronidase (β -GUS). *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S357. 2010.
19. **Farinha Antunes, I., Haisma, H. J., Di Gialleonardo, V., Doorduyn, J., Sijbesma, J. W. A., Elsinga, P. H., Van Waarde, A., Dierckx, R. A., and De Vries, E. F. J.** [18F]-FEAnGA for β -glucuronidase activity in tumors. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S362. 2010.
20. **Farinha Antunes, I., Doorduyn, J., Haisma, H. J., Elsinga, P. H., Dierckx, R. A., and De Vries, E. F. J.** In vivo evaluation of [18F]-FEAnGA for β -glucuronidase activity in neuroinflammation. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S386-S387. 2010.
21. Fiebrich, H., **De Jong, J. R., Kema, I. P., Koopmans, K. P., Sluiter, W., Dierckx, R. A., Walenkamp, A. M., Links, T. P., De Vries, E. G., and Brouwers, A. H.** Total 18F-DOPA PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S301. 2010.
22. Fiebrich, H., Siemerink, E. J. M., Hospers, G. A., **Dierckx, R. A., De Vries, E. G., and Brouwers, A. H.** 18F-FDG-PET identifies everolimus effects on tumour as well as normal tissues in insulinoma patients on everolimus. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S302. 2010.
23. Fuentes, C. L., Lee, J. A., **Dierckx, R. A.,** and Zaidi, H. Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma using surgical specimen as reference. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S337. 2010.

24. **Glaudemans, A. W., De Vries, E. F. J.,** van Kruchten, M., De Vries, E. G., **Slart, R. H., Dierckx, R. A.,** and Hospers, G. A. 16α -[^{18}F]-fluoro- 17β -estradiol positron emission tomography (FES-PET) to detect ER positive tumor lesions in breast cancer patients with a diagnostic dilemma. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S246. 2010.
25. **Golestani, R., De Haas, H.,** Petrov, A. D., Bitsch, N., Kietselaer, B., Stolk, L. M., Heidendal, G. A., Hofstra, L., Tio, R. A., Zeebregts, C. J., **Dierckx, R. A.,** Reutelingsperger, C. P., **Boersma, H. H.,** and Narula, J. Minocyclin inhibits myocardial cell death in animal models of myocardial ischemia and reperfusion. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S240. 2010.
26. **Golestani, R.,** Hillege, H. L., Tio, R. A., Zeilstra, A., Zeebregts, C. J., **Boersma, H. H., Dierckx, R. A., and Slart, R. H.** Abdominal aortic calcification: a strong risk factor for cardiovascular mortality. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S272. 2010.
27. Huynh, H. K., **Willemsen, A. T. M.,** Beers, C. M., Lont, R. J., Laan, E., Jansen, M., Sand, M., **Dierckx, R. A.,** Weijmar-Schultz, W. C. M., and Holstege, G. Hyposexual desire disorder (HDD) women have less brain activation and de-activation than healthy women in response to visual sexual stimuli. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S387. 2010.
28. **Lazarenko, S.,** Serano, A., Zeebregts, C. J., Tio, R. A., **Signore, A., Willemsen, A. T. M., Dierckx, R. A., and Slart, R. H.** Gated ^{13}N -ammonia PET for the evaluation of left ventricular ejection fraction and volumes: comparison of 2 different software packages. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S386. 2010.
29. **Lazarenko, S., Willemsen, A. T. M., Paans, A. M. J., Dierckx, R. A.,** Tio, R. A., and **Slart, R. H.** Evaluation of the different software programs for the left ventricular volume assessment by FDG PET validated by MRI. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S386. 2010.
30. **Lemstra C, de Jong IJ, Leliveld AM, Brouwers AM.** Evaluation of lymphoscintigraphy and sentinel node biopsy in patients with penile carcinoma. J Nucl Med **:****,2010 [oral presentation, SNM Annual Meeting, Salt Lake City, UT, USA]
31. **Lub-de Hooge, M. N.,** Nagengast, W. B., **Brouwers, A. H., De Jong, J. R.,** Hollema, H., **Dierckx, R. A.,** Mulder, N. H., De Vries, E. G., Hoekstra, H. J., and Hospers, G. A. VEGF-SPECT with ^{111}In -bevacizumab in stage III/IV melanoma patients. Eur.J.Nucl.Med.Mol.Imaging 37[Suppl.2], S217. 2010.

32. **Lub-de Hooge, M. N.,** Nagengast, W. B., Gietema, J. A., Oosting, S. F., De Korte, M. A., Warnders, F., Timmer-Bosscha, H., Hospers, G. A., **De Jong, J. R.,** Den Dunnen, W. F., Hollema, H., **Dierckx, R. A.,** and De Vries, E. G. VEGF Immuno-PET with ⁸⁹Zr-ranibizumab during sunitinib treatment. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S288. 2010.
33. **Maas, B., Elsinga, P. H.,** Collier, T. L., **Dierckx, R. A.,** and **Luurtssema, G.** Optimizing radio synthesis of hypoxia tracer [¹⁸F]FAZA using microfluidic chemistry. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S316. 2010.
34. Masteling, M. M., Tio, R. A., **Boersma, H. H.,** Tietge, U. J., De Boer, J., **Dierckx, R. A.,** Zeebregts, C. J., and **Slart, R. H.** Evaluation of FDG uPET imaging in atherosclerotic plaques after CEA: focus on resolution improvement. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S376. 2010.
35. **Matusiak, N.,** Tuin, A. W., Overkleeft, H. S., Bischoff, R., Rozeveld, D., **Ramakrishnan, N. K., Rybczynska, A. A., Dierckx, R. A., Van Waarde, A.,** and **Elsinga, P. H.** Comparison of two radiolabelling approaches of an hydroxamate-based MMP inhibitor, ML5, for PET and SPECT: ¹⁸F-FB-ML5 vs ^{99m}Tc-(HYNIC-ML5)(tricine 2). *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S286. 2010.
36. **Medema, J., Lub-de Hooge, M. N., Brouwers, A. H.,** Dekker, A., Van Veen, H. J., **Dierckx, R. A.,** and **Van Zanten, A. K.** Ten years of experience with quality management in the nuclear medicine department. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S344. 2010.
37. **Mirfeizi, L., Van Waarde, A., Rybczynska, A. A.,** Campbell-Verduyn, L. S., Feringa, B. L., **Dierckx, R. A.,** and **Elsinga, P. H.** Synthesis and evaluation of racemic ¹⁸F-PEG triazole carazolol (¹⁸F-PTC) as a novel cerebral beta-adrenoceptor PET ligand. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl 2], S205-S206. 2010.
38. **Mirfeizi, L., Dierckx, R. A.,** Campbell-Verduyn, L. S., Feringa, B. L., and **Elsinga, P. H.** Synthesis of ¹⁸F-precursors for ¹⁸F-click chemistry. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S241. 2010.
39. **Mirfeizi, L., Yu, Z.,** Campbell-Verduyn, L. S., Feringa, B. L., **Dierckx, R. A.,** De Jong, I. J., Helfrich, W., and **Elsinga, P. H.** Synthesis of a ¹⁸F-bombesin derivative prepared by click chemistry. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S316. 2010.

40. Oosting SF, Nagengast WB, Oude Munnink TH, **Lub-de Hooge MN, Brouwers AH, Glaudemans AWJM**, De Jong IJ, Scherer SJ, Gietema JA, De Vries EGE. 89Zr-bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification. *Eur J Cancer*; 8 (7):72. (Suppl. Abstract 221).
41. **Pruim J**. Good Clinical Practice in a Nuclear Medicine Department. *World J Nucl Med* 9(Suppl. 1):S-78,2010.
42. **Ramakrishnan, N. K., Rybczynska, A. A., Visser, A. K. D., Van Waarde, A., Elsinga, P. H.**, Ishiwata, K., Luiten, P. G. M., and **Dierckx, R. A.** Sigma-1 receptors in healthy ageing: Brain receptor density in young and aged rats assessed with 11C-SA4503 and microPET. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S259. 2010.
43. **Rybczynska, A. A.**, De Bruyn, M., **Elsinga, P. H., Dierckx, R. A.**, Helfrich, W., Bremer, E., and **Van Waarde, A.** Cancer cell killing by σ -ligands and TRAIL fusion protein: monitoring synergy with PET. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S298. 2010.
44. **Rybczynska, A. A.**, De Bruyn, M., **Ramakrishnan, N. K., Sijbesma, J. W. A., Dierckx, R. A., and Van Waarde, A.** MicroPET study of sigma ligand treatment in an animal model of melanoma. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S310. 2010.
45. **Slart, R. H., Mirankova, O.**, Tio, R. A., Elvan, A., and **Dierckx, R. A.** Identification of the role of sympathetic innervation in the modulation of the arrhythmogenic substrate in patients with increased risk of sudden death due to ventricular tachy-arrhythmias in the setting of coronary artery disease. A pilot study. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S224-S225. 2010.
46. **Slart, R. H.**, Tio, R. A., Van der Vleuten, P. A., Willems, T. P., Lubbers, D. D., Van Veldhuisen, D., and **Dierckx, R. A.** Myocardial perfusion reserve and contractile pattern after beta-blocker therapy in patients with idiopathic dilated cardiomyopathy. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S376. 2010.
47. **Slart, R. H.**, De Waal, E. G. M., **Dierckx, R. A.**, and Vellenga, E. Value of FDG-PET and somatostatin receptor scintigraphy for detecting multiple myeloma activity in patients with relapsing disease. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S437. 2010.

48. **Slart, R. H.**, Tio, R. A., Hillege, H. L., Zeebregts, C. J., Zijlstra, F., De Sutter, J., Van Veldhuisen, D., and **Dierckx, R. A.** Myocardial perfusion reserve after a PET-driven revascularization: a stronger prognostic factor than left ventricular ejection fraction. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S322. 2010.
49. Stojanov, K., Zuhorn, I. S., Hoekstra, D., **Van Waarde, A., Dierckx, R. A., and De Vries, E. F. J.** Tracking of radiolabeled neural stem cells with PET and planar scintigraphy. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S307. 2010.
50. **Sturkenboom.M.G., Lub-de Hooge, M. N., Dierckx, R. A.,** Van Imhoff, G. W., Kluin-Nelemans, H. C., and Kosterink, J. G. W. Tumour uptake of ⁸⁹Zr-alemtuzumab compared to ¹¹¹In-IgG in human non-Hodgkin's B-cell lymphoma bearing mice. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S289. 2010.
- 51 **Van Waarde, A., Rybczynska, A. A., Paul, S., Khanapur, S., Sijbesma, J. W. A.,** Ishiwata, K., **Elsinga, P. H., and Dierckx, R. A.** Visualization of adenosine A1 receptors in rat brain, using ¹¹C-MPDX and microPET: effect of raised levels of extracellular adenosine. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S209-S210. 2010.
52. Verbeek, H. H. G., **Koopmans, K. P.,** De Groot, J. W. B., Plukker, J. T., **Dierckx, R. A., Brouwers, A. H.,** and Links, T. P. Value of ¹⁸F-FDG-PET and ¹⁸F-DOPA-PET in detection of biochemically progressive medullary thyroid carcinoma. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S290. 2010.
53. **Visser, A. K. D., Van Waarde, A., Ramakrishnan, N. K., Rybczynska, A. A., Willemsen, A. T. M.,** Kema, I. P., and **Dierckx, R. A.** Validation of [¹¹C]-5-HTP for measurement of serotonin synthesis in the rat brain, using microPET. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S386. 2010.
54. **Wiegers, J., Medema, J., Willemsen, A. T. M., De Vries, E. F. J., Dierckx, R. A., and Pruim, J.** Implementation of GCP: Impact for nuclear medicine techniques. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S492. 2010.
55. **Wierds, R., Lazarenko, S., De Jong, J. R., Segbers, M., Paans, A. M. J., Dierckx, R. A., and Willemsen, A. T. M.** Influence of high-definition and time-of-flight reconstruction techniques on recovery coefficients of PET images. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S335. 2010.
56. **Wierds, R., De Jong, J. R., Lazarenko, S., Segbers, M., Paans, A. M. J., Dierckx, R. A., and Willemsen, A. T. M.** Factors influencing the PET image quality of the Siemens Biograph mCT. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S335. 2010.

57. **Willemsen, A. T. M., Segbers, M., and Dierckx, R. A.** Dopamine D2 receptor occupancy studies with PET and 11C-raclopride revisited. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S308. 2010.
58. **Wu, C., Van der Have, F., De Jong, J. R., Dierckx, R. A., Paans, A. M. J., and Beekman, F. J.** Contour-based attenuation correction for multi-pinhole SPECT. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S285. 2010.
59. **Wu, C., De Jong, J. R., Terwisscha van Scheltinga, A., Sijbesma, J. W. A., Lub-de Hooge, M. N., Dierckx, R. A., and Van Waarde, A.** Molecular imaging in mice using a MILabs U-SPECT II camera. *Eur.J.Nucl.Med.Mol.Imaging* 37[Suppl.2], S306. 2010.

Invited lectures, Conference proceedings, etc

1. De Groot DMG, **Dierckx RA**, Kuper F, Heerschap A, Stierum R, Veltien A, **De Vries EFJ, van Waarde A**, Wolterbeek A, Radonjic M. In vivo imaging and gene expression profiling: Improved safety testing and 50% animal reduction. European Partnership for Alternative Approaches to Animal Testing, Annual Conference, Brussels, Belgium 2010.
2. **De Klerk OL.** The impact of depressive disorders and treatment with an antidepressant on the activity of P-glycoprotein at the blood-brain barrier Oral presentation at the ISAD (International Society for Affective Disorders), Vancouver, Canada, April 15-19, 2010
3. **De Klerk OL.** The impact of P-glycoprotein on antidepressant function. Invited speaker at the BAP (British Association of Psychopharmacology), Harrogate, UK, July 12-15, 2010
4. **De Klerk OL.** PET imaging of P-glycoprotein in psychiatric disorders. Invited speaker at the ICMPP (International Conference Meeting on Psychiatry and Psychopharmacology), Copenhagen, Denmark, Sept 21-24 2010
5. **De Vries EFJ,** PET-CT in brain inflammation. Morphological and functional imaging: a course of PET and CT fusion imaging. Rome, Italy, January 20-23, 2010.
6. **Elsinga PH.** Tracer development for evaluation of lung cancer, NVNG, Deventer, 2010.
7. **Elsinga PH.** Presentation as representative of PCMM-consortium, CTMM Annual Meeting, Utrecht, 2010.

8. **Elsinga PH.** Symposium At Osborne, 2010, “Ontwikkeling van PET en toenemende vraag radionucliden en radiofarmaca”, **keynote speaker.**
9. **Pruim J.** Good clinical practice in nuclear medicine. Quality through transparency. Congress of the World Federation of Nuclear Medicine and Biology, Cape Town, South Africa, September 22, 2010.
10. **Pruim J.** Scintigraphic Diagnostics Of Infection and Inflammation In Orthopedics. Erasmus Exchange, University of South Bohemia, Ceske Budejovice, Czech Republic, February 25, 2010.
11. **Pruim J.** Scintigraphic Diagnostics of Neuroendocrine Tumors. Erasmus Exchange, University of South Bohemia, Ceske Budejovice, Czech Republic, February 25, 2010.
12. **Ramakrishnan NK, Rybczynska AA, Visser AKD, van Waarde A, Nijholt IM, Luiten PGM, Dierckx RA.** Sigma-1 receptors in healthy aging: brain receptor density in aged and young rats assessed with microPET and ¹¹C-SA4503. Annual Meeting FENS, Amsterdam, 2010 [poster presentation]
13. **Ramakrishnan NK, Visser AKD, Rybczynska AA, van Waarde A.** Quantification of sigma-1 receptors in rat brain using ¹¹C-SA4503 and microPET. Indian Pharmaceutical Congress, India, 2010 [poster presentation]
14. van Kruchten M, **Glaudemans A, de Vries EFJ, Schröder CP, de Vries EGE, Hospers GA.** 16^α-[18F]fluoro-17β-estradiol (FES)-PET to detect ER-positive tumor lesions in breast cancer patients presenting with a diagnostic dilemma. American Society of Clinical Oncology Annual Meeting, 2010, abstract 1087.
15. **van Waarde A.** PET imaging: Assessment of in vivo biochemistry. Course on Functional Neuroscience. BCN Research Masters, Graduate School BCN, Groningen, September 20, 2010 [2 invited lectures]
16. **van Waarde A.** Small Animal PET: Principles, Background, Applications. Topmaster II MPD 2009 Course on Research Methods, Groningen, November 17, 2009 [2 invited lectures]
17. **van Waarde A.** A positron emission tomography and microCT for small animal imaging. Lecture, visitation of small animal imaging facilities by N W O, evaluation of output in 2006-2010. Groningen, November 5, 2010.
18. **Visser AKD, van Waarde A, Ramakrishnan NK, Willemsen ATM, Kema IP, Dierckx RA.** Validation of [¹¹C]-5-HTP for measurement of serotonin synthesis in the rat brain, using microPET. Annual Meeting FENS, Amsterdam, 2010 [poster presentation]

Book Chapters

1. **Brouwers AH, Koopmans KP, Dierckx RAJO, Elsinga PH.** DOPA PET-CT. In: PET-CT Beyond FDG-A Quick Guide to Image Interpretation. Editors: Fanti S, Farsad M, Mansi L. Springer-Verlag, Berlin Heidelberg, 2010; pp.161-179.
2. **Brouwers AH, Koopmans KP, Dierckx RAJO, Elsinga PH.** HTP PET-CT. In: PET-CT Beyond FDG-A Quick Guide to Image Interpretation. Editors: Fanti S, Farsad M, Mansi L. Springer-Verlag, Berlin Heidelberg, 2010; 221-229.
3. **De Vries EF, Glaudemans AWJ, Schroder CP, Hospers AG.** PET imaging of hormonal receptors. In: PET-CT Beyond FDG-A Quick Guide to Image Interpretation. Editors: Fanti S, Farsad M, Mansi L. Springer-Verlag, Berlin Heidelberg, 2010; pp.213-219.